Reaktionsgleichung
[Cl:1][C:2]1[N:3]=[C:4]2[NH:12][C@H:11]([C:13]([F:16])([F:15])[F:14])[CH2:10][CH2:9][N:5]2[C:6](=[O:8])[CH:7]=1.C(=O)([O-])[O-].[Cs+].[Cs+].Br[CH2:24][C:25](=[O:29])[CH:26]([CH3:28])[CH3:27]>C(#N)C>[Cl:1][C:2]1[N:3]=[C:4]2[N:12]([CH2:24][C:25](=[O:29])[CH:26]([CH3:28])[CH3:27])[C@H:11]([C:13]([F:14])([F:15])[F:16])[CH2:10][CH2:9][N:5]2[C:6](=[O:8])[CH:7]=1Komponenten
5
Edukt 3
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
A suspension of 170 mg (0.670 mmol) of (8S)-2-chloro-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 655.21 mg (2.01 mmol) of cesium carbonate in 10 mL of acetonitrile is stirred for 15 minutes at room temperature. 132.75 mg (0.804 mmol) of 1-bromo-3-methylbutan-2-one are then added. After stirring overnight at room temperature, the reaction mixture is evaporated and the residue is taken up in water and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and evaporated to dryness to give 220 mg of (8S)-2-chloro-9-(3-methyl-2-oxobutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, corresponding to the following characteristics:
Aufarbeitung
- stirringAfter stirring overnight at room temperature
- customthe reaction mixture is evaporated
- extractionextracted with ethyl acetate
- dry with materialThe organic phase is dried over magnesium sulfate
- customevaporated to dryness
Quellen und Nachweise
- ORD-Eintrag
- ord-2be852f99f4743ef9e1c4208a1720b16
- Quelldatensatz
- uspto-grants-2016_04
- Patentnummer
- US09321790B2
Verknüpfte Notizen
Wird geladen…